Literature DB >> 25145925

Ebstein anomaly: assessment, management, and timing of intervention.

Puneeta Arya1, Rebecca Beroukhim.   

Abstract

OPINION STATEMENT: Ebstein anomaly is a developmental abnormality of the tricuspid valve and right ventricle that results in tricuspid regurgitation and right heart enlargement. Because of the variation in clinical severity and associated findings, patients require a detailed, well-tailored evaluation. For these reasons, management of adults with Ebstein anomaly should take place in a center with expertise in adult congenital heart disease. In many patients, the decision regarding if and when to perform surgery remains controversial, largely because of a lack of published data demonstrating improved postoperative symptoms and survival compared to the natural history of the disease. Because standard two-dimensional echocardiography and cardiovascular magnetic resonance imaging planes do not provide the necessary data to preoperatively manage patients, comprehensive echocardiography and cardiovascular magnetic resonance imaging protocols by experts trained in congenital heart disease are essential in the preoperative management of patients with Ebstein anomaly. As patients may be unaware of their exercise limitations, and for prognostic value, serial cardiopulmonary exercise stress testing is very useful in the evaluation of Ebstein anomaly patients. Surgical tricuspid valve repair historically has not been highly successful because of the marked distortion of tricuspid valve leaflets and right ventricular pathology. Over the last several years, reports of newer surgical techniques to repair the valve, with concurrent advances in arrhythmia management of patients hold promise for improved long term outcomes of patients with Ebstein anomaly. However, because Ebstein anomaly is rare and tricuspid valve repair remains technically challenging, the newer valve repair techniques have not yet gained widespread acceptance throughout the adult congenital heart disease community.

Entities:  

Year:  2014        PMID: 25145925     DOI: 10.1007/s11936-014-0338-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  45 in total

1.  Cone reconstruction in Ebstein's anomaly repair: early and long-term results.

Authors:  José Pedro da Silva; Luciana da Fonseca da Silva; Luiz Felipe P Moreira; Lilian Maria Lopez; Sônia Meiken Franchi; Alessandro Cavalcante Lianza; José Francisco Baumgratz; Glaucia Maria P Tavares
Journal:  Arq Bras Cardiol       Date:  2011-08-05       Impact factor: 2.000

2.  Pregnancy outcomes in women with Ebstein's anomaly.

Authors:  Weixiu Zhao; Hua Liu; Ran Feng; Jianhua Lin
Journal:  Arch Gynecol Obstet       Date:  2012-05-27       Impact factor: 2.344

3.  Mimics of Ebstein's anomaly.

Authors:  N M Ammash; C A Warnes; H M Connolly; G K Danielson; J B Seward
Journal:  Am Heart J       Date:  1997-09       Impact factor: 4.749

4.  Strategies for tricuspid re-repair in Ebstein malformation using the cone technique.

Authors:  Joseph A Dearani; Sameh M Said; Harold M Burkhart; Roxann B Pike; Patrick W O'Leary; Frank Cetta
Journal:  Ann Thorac Surg       Date:  2013-06-04       Impact factor: 4.330

Review 5.  Update on interventional electrophysiology in congenital heart disease: evolving solutions for complex hearts.

Authors:  Elizabeth D Sherwin; John K Triedman; Edward P Walsh
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-10

6.  Multiplanar review of three-dimensional echocardiography gives new insights into the morphology of Ebstein's malformation.

Authors:  Tara Bharucha; Robert H Anderson; Zek S Lim; Joseph J Vettukattil
Journal:  Cardiol Young       Date:  2010-01-19       Impact factor: 1.093

7.  Coronary artery stenosis after radiofrequency catheter ablation of accessory atrioventricular pathways in children with Ebstein's malformation.

Authors:  H Bertram; R Bökenkamp; M Peuster; G Hausdorf; T Paul
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

8.  Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor outcome.

Authors:  Ada Stefanescu; Eric A Macklin; Elaine Lin; David M Dudzinski; Jacob Johnson; Kevin F Kennedy; Daniel Jacoby; Doreen DeFaria Yeh; Gregory D Lewis; Robert W Yeh; Richard Liberthson; George Lui; Ami B Bhatt
Journal:  Am J Cardiol       Date:  2013-12-12       Impact factor: 2.778

Review 9.  26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: congenital heart disease.

Authors:  T P Graham; J T Bricker; F W James; W B Strong
Journal:  J Am Coll Cardiol       Date:  1994-10       Impact factor: 24.094

10.  Risk factors for maternal and fetal outcome in pregnancy complicated by Ebstein anomaly.

Authors:  Shinji Katsuragi; Chizuko Kamiya; Kaoru Yamanaka; Reiko Neki; Takekazu Miyoshi; Naoko Iwanaga; Chinami Horiuchi; Hiroaki Tanaka; Jun Yoshimatsu; Koichiro Niwa; Tomoaki Ikeda
Journal:  Am J Obstet Gynecol       Date:  2013-07-13       Impact factor: 8.661

View more
  3 in total

1.  A Rare Manifestation of Asymptomatic Ebstein's Anomaly with Tricuspid Valve Endocarditis.

Authors:  Carmel Moazez; Vicken Zeitjian; Christian Breburda; Ranjini Roy
Journal:  Case Rep Cardiol       Date:  2017-10-25

2.  Left ventricular synchrony, torsion, and recoil mechanics in Ebstein's anomaly: insights from cardiovascular magnetic resonance.

Authors:  Michael Steinmetz; Simon Usenbenz; Johannes Tammo Kowallick; Olga Hösch; Wieland Staab; Torben Lange; Shelby Kutty; Joachim Lotz; Gerd Hasenfuß; Thomas Paul; Andreas Schuster
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-14       Impact factor: 5.364

3.  Cardiovascular magnetic resonance evidence of myocardial fibrosis and its clinical significance in adolescent and adult patients with Ebstein's anomaly.

Authors:  Dan Yang; Xiao Li; Jia-Yu Sun; Wei Cheng; Andreas Greiser; Tian-Jing Zhang; Hong Liu; Ke Wan; Yong Luo; Qi An; Yiu-Cho Chung; Yuchi Han; Yu-Cheng Chen
Journal:  J Cardiovasc Magn Reson       Date:  2018-09-27       Impact factor: 5.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.